Neuralink competitor Paradromics secures investment from Saudi Arabia’s Neom

Neuralink competitor Paradromics secures investment from Saudi Arabia’s Neom


Paradromics scientists at work

Source: Paradromics

Texas-based neurotech startup Paradromics on Wednesday announced a strategic partnership with Saudi Arabia’s Neom and said it will establish a Brain-Computer Interface Center of Excellence in the region.

Neom is a developing area within northwest Saudi Arabia that’s touted as “a hub for innovation,” according to its website. The area’s strategic investment arm, the Neom Investment Fund, led the partnership. Paradromics declined to disclose the investment amount.

Paradromics is building a brain-computer interface, or a BCI, which is a system that deciphers brain signals and translates them into commands for external technologies. The company will work with Neom to “advance the development of BCI-based therapies” and set up the “premier center for BCI-based healthcare” in the Middle East and North Africa, it said in a release.

“Working together, we can accelerate the rate of innovation in BCI and expand access to impactful BCI-based therapies.” Paradromics CEO Matt Angle said in a statement.

Paradromics is one of several companies racing to commercialize BCIs, including Elon Musk’s startup Neuralink. Earlier this month, Neuralink announced it has implanted three human patients with its technology, according to a blog post. Precision Neuroscience and Jeff Bezos and Bill Gates-backed Synchron have also implanted their systems in humans.

None of these companies have secured the FDA’s final stamp of approval.

Paradromics’ BCI, the Connexus Direct Data Interface, is an array of tiny electrodes designed to be implanted directly into the brain tissue. The system could eventually help patients with severe paralysis regain their ability to communicate by deciphering their neural signals. 

The company is gearing up to launch its first human trial this year, and announced its official patient registry in July. Paradromics’ technology has not yet been approved by the U.S. Food and Drug Administration, and it still has a long way to go before commercialization. In 2023, the company received the FDA’s Breakthrough Device designation, which aims to help accelerate the go-to-market process.

Watch: Inside Paradromics, the Neuralink competitor hoping to commercialize brain implants before the end of the decade

Inside Paradromics, the Neuralink competitor hoping to commercialize brain implants before the end of the decade



Source

Rocket maker Firefly Aerospace files to go public under ticker FLY
Technology

Rocket maker Firefly Aerospace files to go public under ticker FLY

Firefly Aerospace CEO Jason Kim sits for an interview at the Firefly Aerospace mission operations center in Leander, Texas, on July 9, 2025. Sergio Flores | Reuters Rocket maker Firefly Aerospace filed for an initial public offering on Friday, with plans to trade under the ticker symbol “FLY” on the Nasdaq. Firefly’s planned offering comes […]

Read More
Robinhood is up 160% this year, but several obstacles are ahead
Technology

Robinhood is up 160% this year, but several obstacles are ahead

Robinhood stock hit an all-time high Friday as the financial services platform continued to rip higher this year, along with bitcoin and other crypto stocks. Robinhood, up more than 160% in 2025, hit an intraday high above $101 before pulling back and closing slightly lower. The reversal came after a Bloomberg report that JPMorgan plans […]

Read More
Bill Gates says Trump’s cuts to USAID are devastating: ‘It’s not too late to reverse them’
Technology

Bill Gates says Trump’s cuts to USAID are devastating: ‘It’s not too late to reverse them’

Bill Gates speaks with Reuters during an interview in New York City, U.S., May 8, 2025. Mike Segar | Reuters Bill Gates, the philanthropist and Microsoft co-founder, on Friday said it’s not too late to reinstate international aid funding that President Donald Trump cut off. The Trump administration placed staff members at the U.S. Agency […]

Read More